Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PSTI

Pluristem Therapeutics (PSTI) Stock Price, News & Analysis

Pluristem Therapeutics logo

About Pluristem Therapeutics Stock (NASDAQ:PSTI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$1.58
52-Week Range
N/A
Volume
2,128 shs
Average Volume
715,259 shs
Market Capitalization
$32.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PSTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTI Stock News Headlines

NBRVF Nabriva Therapeutics plc
Pluri CEO Issues Shareholder Update
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

PSTI Stock Analysis - Frequently Asked Questions

Pluristem Therapeutics Inc. (NASDAQ:PSTI) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05.

Shares of Pluristem Therapeutics reverse split on the morning of Thursday, July 25th 2019.The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluristem Therapeutics investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Meta Platforms (META), Gilead Sciences (GILD), Novavax (NVAX) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/08/2021
Today
7/02/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PSTI
Employees
153
Year Founded
2003

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.87 million
Pretax Margin
-20,024.79%

Debt

Sales & Book Value

Annual Sales
$20 thousand
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
N/A

Miscellaneous

Free Float
30,601,000
Market Cap
$32.35 million
Optionable
Optionable
Beta
1.91

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PSTI) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners